Bimzelx (bimekizumab-bkzx) — Point32Health
Plaque psoriasis
Preferred products
- Cimzia
- Enbrel
- Humira
- Otezla
- Skyrizi
- Yesintek
- Taltz
- Tremfya
Initial criteria
- Documented diagnosis of plaque psoriasis
- Patient age ≥ 6 years
- Prescribed by or in consultation with a dermatologist
- Documentation of one (1) of the following: a. Both of the following: i. One (1) of the following: 1. Inadequate response to one (1), or contraindication to all of the following topical therapies: corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar OR 2. Previous treatment with a biologic agent indicated for the requested use AND ii. Trial and failure with two (2), or contraindication to all of the following: Cimzia, Enbrel, Humira, Otezla, Skyrizi, Yesintek, Taltz, Tremfya OR b. The patient is new to the plan and stable on Bimzelx and the prescribing physician has documented that changing to a preferred product would result in adverse clinical outcomes